BURLINGTON, Ontario–(BUSINESS WIRE)–Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation, announces that further to its press release dated August 29, 2022, the Company and its auditors are continuing to work diligently to complete the audit of the Company’s annual financial statements for the fiscal … [Read more…]
Report available at corporateresponsibility.unither.com SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation (PBC), today announced the release of its third annual Corporate Responsibility Report with 2021 highlights, providing stakeholders important information regarding the company’s commitment to environmental, social, and governance (ESG) priorities. Contained within the report … [Read more…]
CRYSTAL LAKE, Ill.–(BUSINESS WIRE)–AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, announced today that Matt Trerotola has joined its Board of Directors. Matt has served as the President and Chief Executive Officer for Enovis Corporation (formerly Colfax), an innovation-driven medical technology company, since … [Read more…]
Company to hold conference call and webcast on Monday, September 12th at 4:30 PM Eastern Standard Time (EST) VANCOUVER, British Columbia & SEATTLE–(BUSINESS WIRE)–Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today presented preliminary results from the company’s Phase 1 clinical trial evaluating zanidatamab zovodotin (ZW49) for the treatment of HER2-positive tumors. … [Read more…]
– ALPN-303 well-tolerated in a Phase 1 healthy volunteer study with on-target effects on key biomarkers, supporting a highly competitive, potentially best in class profile – – Davoceticept (ALPN-202) demonstrates encouraging outcomes, especially in renal cell carcinoma, as monotherapy and in combination with pembrolizumab in ongoing NEON-1 and NEON-2 studies respectively – – Alpine management … [Read more…]
NASHVILLE, Tenn.–(BUSINESS WIRE)–Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings (“Revance” or the “Company”), today announced a proposed underwritten public offering of $150 million of its common stock. In addition, Revance expects to grant the underwriters a 30-day option to purchase up to an additional 15% … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Breast Cancer Liquid Biopsy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027” report has been added to ResearchAndMarkets.com’s offering. The global breast cancer liquid biopsy market size reached US$ 90.79 Million in 2021. Looking forward, the publisher expects the market to reach US$ 271.77 Million by 2027, exhibiting a CAGR … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “China Tumor Ablation Landscape, Procedure and Technology Trends, Brand Perception, Competitive Intelligence and Future Outlook” report has been added to ResearchAndMarkets.com’s offering. Why Buy This Report First-ever syndicated report with robust insights from Interventional Radiologists Helps in understanding the current market scenario of tumor ablation in China Includes 100+ slide MS PowerPoint report … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “China Peripheral Artery Disease Interventions Landscape, Procedure and Technology Trends, Brand Perception, Competitive Intelligence and Future Outlook” report has been added to ResearchAndMarkets.com’s offering. Why Buy This Report First-ever syndicated report with robust insights from Interventional Cardiologists, Vascular Surgeons, and Interventional Radiologists Helps in understanding the current market scenario of the peripheral artery … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “China Percutaneous Coronary Interventions Landscape, Procedure and Technology Trends, Brand Perception, Competitive Intelligence and Future Outlook” report has been added to ResearchAndMarkets.com’s offering. Why Buy This Report First-ever syndicated report with robust insights from Interventional Cardiologists and Cardiologists Helps in understanding the current market scenario of the percutaneous coronary interventions in China Includes … [Read more…]
